Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update
The Lancet Neurology
Volume 16, No. 3, p238–250, March 2017
Dr Valerie Voon, MD, Dr Valerie Voon, Dr Valerie Voon, Prof T Celeste Napier, PhD, Prof Michael J Frank, PhD, Veronique Sgambato-Faure, PhD, Prof Anthony A Grace, PhD, Prof Maria Rodriguez-Oroz, MD, Prof Jose Obeso, MD, Erwan Bezard, PhD, Pierre-Olivier Fernagut, PhD
Dopaminergic medications used in the treatment of patients with Parkinson’s disease are associated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control disorders also known as behavioural addictions. Levodopa-induced dyskinesias occur in up to 80% of patients with Parkinson’s after a few years of chronic treatment. Impulse control disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and compulsive shopping occur in about 17% of patients with Parkinson’s disease on dopamine agonists. These behaviours reflect the interactions of the dopaminergic medications with the individual’s susceptibility, and the underlying neurobiology of Parkinson’s disease.